Grimes & Company’s ImmunityBio IBRX Stock Holding History

Grimes & Company’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$467K	Hold	53,307	–	–	0.01%	321
2026 Q1	$409K	Sell	53,307 -5,129	-9%	-$35.1K	0.01%	322
2025 Q4	$116K	Hold	58,436	–	–	﹤0.01%	451
2025 Q3	$144K	Hold	58,436	–	–	﹤0.01%	443
2025 Q2	$154K	Buy	58,436 +48,436	+484%	+$130K	﹤0.01%	404
2025 Q1	$30.1K	Hold	10,000	–	–	﹤0.01%	366
2024 Q4	$25.6K	Hold	10,000	–	–	﹤0.01%	379
2024 Q3	$37.2K	Hold	10,000	–	–	﹤0.01%	359
2024 Q2	$63.2K	Hold	10,000	–	–	﹤0.01%	340
2024 Q1	$53.7K	Hold	10,000	–	–	﹤0.01%	335
2023 Q4	$50.2K	Hold	10,000	–	–	﹤0.01%	322
2023 Q3	$16.9K	Hold	10,000	–	–	﹤0.01%	304
2023 Q2	$27.8K	Buy	+10,000	New	+$28.3K	﹤0.01%	306

Other funds holding IBRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Grimes & Company's IBRX Position: Q2 2026 in Review

Grimes & Company held its ImmunityBio (IBRX) position steady in Q2 2026 at 53,307 shares worth $467K. The position accounts for 0.01% of the portfolio, ranked #321.

Grimes & Company first reported a position in IBRX in Q2 2023 and has held it in 13 quarters since. 405 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

Grimes & Company held 53,307 shares of ImmunityBio worth $467K as of Q2 2026.
Grimes & Company left its ImmunityBio share count unchanged in Q2 2026.
ImmunityBio made up 0.01% of Grimes & Company's portfolio in Q2 2026, its #321 holding.
Grimes & Company first reported a position in ImmunityBio in Q2 2023 and has held it in 13 quarters since.
405 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Grimes & Company's 13F filing for Q2 2026, filed 17 Jul 2026.